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Abstarct: 
Guillain-Barré Syndrome represents a condition that is acutely evolving, immune mediated and inflammatory 
disorder of the peripheral nervous system. Clinical hallmarks include flaccid muscle paresis and areflexia with 
increased cerebrospinal fluid protein content which can be caused by infection, trauma, surgery and blood 
transfusion. Early diagnosis and proper treatment should occur as there can be potential ventillatory failure 
and cardiovascular instability in some patients. Here we discuss a case of 37 year old female patient with 
complaints of weakness, inability to move right upper limb and lower limb for past 6 days. She had a history of 
spinal cord trauma before 5 months, which is considered to be a triggering factor that leads to Guillain-Barre 
Syndrome. The standard treatment for Guillain-Barré Syndrome is Plasmapheresis or Immunoglobulin, in our 
case the patient was treated with immunoglobulin for five days. Her condition was improved and thus she was 
discharged from the hospital. 
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INTRODUCTION: 
Guillain-Barré Syndrome (GBS) is a complicated 
degenerative neurological disorder affecting 1 
person in 100,000. It can be acute or chronic in 
nature in which the immune system attacks healthy 
nerve cells in peripheral nervous system and it is 
characterized by progressive, proximal and distal 
tingling, weakness and numbness [1]. Muscle 
weakness progress to temporary paralysis of 
respiratory muscle, difficulty with chewing and 
swallowing, difficulty with digestion and bladder 
control, difficulty with eye movement and speech 
and slow heart rate and low blood pressure [2].  
There are several types of GBS, among them most 
common type is acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP) and other types are 
acute motor axonal neuropathy (AMAN), acute 
motor sensory axonal neuropathy (AMSAN) and 
Miller Fisher syndrome [3]. The exact cause of 
GBS is unknown. It can be triggered by infection, 
vaccination and surgery.   
 
Early diagnosis and prompt treatment should occur 
as it can cause potential ventilatory failure and 
cardiovascular instability[4]. There is no cure for 
GBS. But two types of treatments plasmapheresis 
and immunoglobulin therapy can hasten recovery 
and reduce the severity of illness [5]. 
 
CASE REPORT: 
 A 35 year old female patient was admitted in 
neurology department of a tertiary care teaching 
hospital with complaints of weakness, inability to 
move right upper limb and lower limb for past 6 
days, difficulty in turning from side to side, 
regurgitation of food, difficulty in breathing, 
headache, diarrhoea and loss of bowel and bladder  
 
control. Patient had a history of trauma before 5 
months.  The patient was conscious and well 
oriented to time and place. Patient’s vitals were as 
follows B.P- 110/70mmHg and P.R-72bpm. 
Systemic examination showed CVS- S1S2(+), RS- 
BAE(+), P/A-SOFT and CNS examination is in 
table 1. 
 
MRI of cervical spine showed posterior disc bulge 
indenting thecal sac from C3-4 to C6-7 levels. In 
whole spine survey, L5-S1 disc showed posterior 
bulge with annular tear indenting thecal sac 
touching the traversing root at lateral recess. Blood 
investigation revealed slightly elevated ESR of 
32mm/hr. MRI Brain was normal. CSF analysis 
showed increased level of protein (120mg/dl) 
whereas lymphocytes and glucose levels were 
normal. 
 
Based on the subjective and objective evidence the 
patient was diagnosed as a case of Guillain-Barré 
Syndrome following spinal cord trauma. As the 
patient had breathing difficulties and inability to 
move herself, she was shifted to ICU. In ICU she 
received ventillatory assistance, monitoring of 
blood pressure, fluid status and cardiac rhythm. 
The patient received physiotherapy throughout the 
hospital stay. She was treated with intravenous 
Immunoglobulin (IVIG) (0.4g/kg/day), IV fluids, 
Nootropic drugs (Citicoline 250 mg and Piracetam 
200mg), Corticosteroid (16 mg), anti-diarrhoeal 
agent (Loperamide 2mg), H2 receptor antagonist 
(Ranitidine 50 mg) and vitamin B12 supplement. 
After treatment for 5 days patient’s CNS 
examination showed improvement in power, tone 
and reflex and it is showed in table 2. 
 
 
Table 1: CNS Examination before treatment 
 
CNS Right Left 
Tone Upper limb Hypotonic Normal 
Lower limb Hypotonic Hypotonic 
Power Upper limb 1/5 4/5 
Lower limb 1/5 1/5 
Sensation  Upper limb No response  Response 
Lower limb No response No response 
 
 
Table 2: CNS Examination after treatment 
 
CNS Right Left 
Tone Upper limb Normal Normal 
Lower limb Normal Normal 
Power Upper limb 3/5 4/5 
Lower limb 3/5 3/5 
Sensation  Upper limb Response  Response 
Lower limb Response Response 
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DISCUSSION: 
Guillain-Barré Syndrome (GBS) is a rare 
autoimmune disorder in which the body’s immune 
system attacks peripheral nervous system and 
affects the nerves that control muscle movement as 
well as those that are transmit pain, temperature 
and touch sensation [3]. This results in muscle 
weakness and loss of sensation in the legs and/or 
arms. The core clinical feature of GBS is rapidly 
progressive weakness which will reach its peak 
within 4 weeks but most patients reach it within 2 
to 3 weeks [6]. The case reported here had an 
ascending paralysis that was preceded by trauma of 
spinal cord, the only clear precipitating event which 
we infer to be the inducing stimulus for the 
development of GBS. Several mechanisms have 
been suggested for development of GBS following 
traumatic bone injuries like missed viral infections, 
surgical stress and genetic susceptibility. This 
patient showed typical features of GBS with rapid 
development of limb paralysis, breathing 
difficulties, diarrhoea, loss of bowel and bladder 
control, areflexia and sensory loss. The diagnosis 
of GBS is most clinically supported by CSF and 
electro diagnostic criteria. Here the diagnosis was 
made because this case had fulfilled the clinical 
features and satisfied the electrophysiological 
criteria required. The standard treatment of GBS 
includes supportive care and immunotherapy, IVIG 
or plasmapheresis. IVIG is made from donated 
blood consisting of healthy antibodies and they 
helps in stopping the harmful antibodies from 
damaging the nerves.  In this case  the patient was 
treated with intravenous immunoglobulin 
0.4g/kg/day for 5 consecutive days (totally 
2g/kg/day). On the sixth day patient’s condition 
improved and hence she was discharged. 
 
CONCLUSION:  
Guillain-Barré Syndrome is a neurological disorder 
that results primarily in muscle paralysis which 
may in a small percentage leads to death. Therefore 
it is extremely important to identify potential 
severe cases in order to have the appropriate 
investigations and for the appropriate care 
administered. 
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ABBREVIATIONS: 
GBS- Guillain-Barré Syndrome, BP- Blood 
Pressure , PR- Pulse Rate , CVS- 
Cardiovascular System , RS- Respiratory 
System, BAE-Bilateral Air Entry, CNS- 
Central Nervous System, P/A- Per Abdomen, 
ESR-Erythrocyte Sedimentation Rate, MRI- 
Magnet Resonance Imaging, CSF- Cerebrospinal 
Fluid, ICU- Intensive Care Unit, IVIG- Intravenous 
Immunoglobulin, C- Cervical Vertebrae, L- 
Lumbar Vertebrae, S-Sacral Vertebrae 
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